Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRD5A2 | P31213 | 3/20 | 0.51 |
| ▸ | CNR2 | P34972 | 2/20 | 0.48 |
| ▸ | P2RX1 | P51575 | 1/20 | 0.47 |
| ▸ | CES2 | O00748 | 2/20 | 0.47 |
| ▸ | CNR1 | P21554 | 1/20 | 0.47 |
| ▸ | KCNK3 | O14649 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 2/20 | 0.46 |
| ▸ | GLA | P06280 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.44 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29941444 | 1.00 | SRD5A2 (0.51) | SRD5A2CNR2P2RX1CES2CNR1 | |
| SCHEMBL1513062 | 0.87 | KDM4E (0.56) | SRD5A2CNR2P2RX1CES2CNR1 | |
| SCHEMBL5992479 | 0.83 | CNR2 (0.55) | SRD5A2CNR2P2RX1CES2CNR1 | |
| SCHEMBL3486347 | 0.83 | MAPT (0.61) | SRD5A2CNR2P2RX1CES2CNR1 | |
| SCHEMBL9537242 | 0.83 | KDM4E (0.62) | SRD5A2CNR2P2RX1CES2CNR1 | |
| SCHEMBL30070755 | 0.83 | CNR2 (0.55) | SRD5A2CNR2P2RX1CES2CNR1 | |
| SCHEMBL27353325 | 0.82 | GLA (0.55) | SRD5A2CNR2P2RX1CES2CNR1 | |
| SCHEMBL25850063 | 0.82 | TAS2R14 (0.52) | SRD5A2CNR2P2RX1CES2CNR1 | |
| SCHEMBL43771 | 0.80 | ALDH1A1 (0.59) | SRD5A2CES2HPGDALDH1A1MEN1 | |
| SCHEMBL29382489 | 0.80 | ALDH1A1 (0.59) | SRD5A2CES2HPGDALDH1A1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9663476-B2 | Glycine transporter-1 inhibitors | AMGEN INC. (US) | 2017-05-30 | — | — | US | disclosed |
| EP-2947067-A1 | Glycine transporter-1 inhibitors | Amgen, Inc (US) | 2015-11-25 | — | — | EP | disclosed |
| US-20150307457-A1 | GLYCINE TRANSPORTER-1 INHIBITORS | AMGEN INC. (US) | 2015-10-29 | — | — | US | disclosed |
| US-8735383-B2 | Glycine transporter-1 inhibitors | AMGEN INC. (US) | 2014-05-27 | — | — | US | disclosed |
| EP-2041088-B1 | GLYCINE TRANSPORTER-1 INHIBITORS | AMGEN INC (US) | 2014-01-08 | — | — | EP | disclosed |
| CN-102964233-A | Synthetic method of 3, 5-difluoro trifluoromethyl benzophenone | DALIAN JOIN KING BIOCHEM TECH CO LTD | 2013-03-13 | — | — | CN | disclosed |
| CN-102964233-A | Synthetic method of 3, 5-difluoro trifluoromethyl benzophenone | DALIAN JOIN KING BIOCHEM TECH CO LTD | 2013-03-13 | — | — | CN | disclosed |
| EP-2565183-A1 | Glycine transporter-1 inhibitors | Amgen Inc. (US) | 2013-03-06 | — | — | EP | disclosed |
| CN-101479243-B | Glycine transporter-1 inhibitors | AMGEN INC | 2013-01-02 | — | — | CN | disclosed |
| US-8258306-B2 | Glycine transporter-1 inhibitors | AMGEN INC. (US) | 2012-09-04 | — | — | US | disclosed |
| WO-2002010137-A9 | INDAZOLE DERIVATIVES AS JNK INHIBITORS | SIGNAL PHARM INC (US) | 2003-02-06 | — | — | WO | disclosed |
| US-20020103229-A1 | Indazole derivatives as JNK inhibitors and compositions and methods related thereto | SIGNAL PHARMACEUTICALS, LLC | 2002-08-01 | — | — | US | disclosed |
| WO-2002010137-A2 | INDAZOLE DERIVATIVES AS JNK INHIBITORS | SIGNAL PHARMACEUTICALS, INC. (US) | 2002-02-07 | — | — | WO | disclosed |
| EP-0806411-B1 | Anti-viral compounds | LILLY CO ELI (US) | 2001-07-11 | — | — | EP | disclosed |
| US-6127422-A | INHIBITING AN ENVELOPE VIRUS SELECTED FROM THE GROUP CONSISTING OF INFLUENZA BOVINE DIARRHEAL, HEPATITIS C AND TICK BORNE ENCEPHALITIS VIRUS THAT UNDERGOES HEMAGGLUTININ MEDIATED FUSION WITH A HOST CELL; PHENANTHRENE ESTERS | ELI LILLY AND COMPANY (US) | 2000-10-03 | — | — | US | disclosed |
| US-6096917-A | Anti-viral compounds | ELI LILLY AND COMPANY (US) | 2000-08-01 | — | — | US | disclosed |
| WO-1997041849-A1 | ANTI-VIRAL METHOD | ELI LILLY AND COMPANY (US) | 1997-11-13 | — | — | WO | disclosed |
| WO-1997042154-A1 | ANTI-VIRAL COMPOUNDS | ELI LILLY AND COMPANY (US) | 1997-11-13 | — | — | WO | disclosed |
| EP-0806203-A2 | Anti-viral compositions | ELI LILLY AND COMPANY (US) | 1997-11-12 | — | — | EP | disclosed |
| EP-0806411-A2 | Anti-viral compounds | ELI LILLY AND COMPANY (US) | 1997-11-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020103229-A1 | Indazole derivatives as JNK inhibitors and compositions and methods related thereto | MAP3K7, MAP3K1, MAP3K8 | SRD5A2 2761/4885CNR2 1608/4885P2RX1 2126/4885 |
| US-20150307457-A1 | GLYCINE TRANSPORTER-1 INHIBITORS | SLC18A2, SLC7A11, SLC6A5 | SRD5A2 2710/4885CNR2 1604/4885P2RX1 3017/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.